PPARA and metabolic dysfunction-associated steatohepatitis: Currently, most investigational drugs for the treatment of NASH start from a designated cellular target, such PPARα/δ, PPARα/γ, FXR, CCR2/5, SCD-1, ASK-1, ACC, caspase inhibitor, THR-β or a combination of some of them (Friedman et al., 2018).